ModernMedicine Resource Center More Topics

Video

Combination therapy seems best for relief of psoriasis

Combination therapy seems best for relief of psoriasis. Learn about which therapies work in the best combinations for your psoriasis patients.

Treatments for Plaque Psoriasis

Off-label systemic immunomodulators useful for various indicationsAlthough many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.
Secukinumab approved for psoriasis
Secukinumab approved for psoriasisSecukinumab has received FDA approval as a new treatment option in psoriasis. A panel of experts tackles this drug’s uses, benefits, and drawbacks.
Oral options not keeping up with biologicsResearchers analyzed emerging oral drugs for psoriasis and concluded “… the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies.
Study: CME improves psoriasis care
Study: CME improves psoriasis careNew Study suggests dermatologists completing a PI CME on psoriasis significantly improved in important patient care aspects. Learn more.
Researchers isolate psoriasis triggering proteins
Researchers isolate psoriasis triggering proteinsCan targeting differentially regulated proteins reverse or prevent disease?
Final trial phase begins for drug’s plaque-psoriasis indication
Final trial phase begins for drug’s plaque-psoriasis indicationA phase 3 clinical program is under way to further evaluate the efficacy and safety of Cimzia (certolizumab pegol, UCB) in adult patients with moderate to severe chronic plaque psoriasis.
FDA approves secukinumab for adults with psoriasis
FDA approves secukinumab for adults with psoriasisThe FDA announced Wednesday, January 21, that it approved secukinumab (Cosentyx, Novartis Pharmaceuticals Corporation) as a treatment for adults with moderate-to-severe plaque psoriasis.
Important gaps in dermatology research
Important gaps in dermatology researchKevin D. Cooper, M.D., professor and chair of dermatology at Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, and Steven R. Feldman, M.D., Ph.D., professor of dermatology, Wake Forest University School of Medicine, Winston-Salem, N.C., weigh in on important gaps in dermatology research today.
Closing gaps in psoriasis researchA report published in January 2014 identified several gaps in psoriasis research and recommended research targets to address these gaps.
Compliance is shockingly understudied
Compliance is shockingly understudiedGetting patients to use their prescriptions is another story-one that's shockingly understudied in dermatology. Just what works to improve medication adherence has stumped researchers outside dermatology. Several studies are cited.